Created at	Source	Raw Value	Validated value
May 25, 2025, midnight	usa	Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version);Change From Baseline to Week 24 in the MaPS;Number of Participants With TEAEs and TESAEs	Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version);Change From Baseline to Week 24 in the MaPS;Number of Participants With TEAEs and TESAEs
Dec. 2, 2022, 4 p.m.	usa	Evaluate the efficacy of efgartigimod in reducing the severity of post-COVID-19 POTS symptoms;Evaluate the efficacy of efgartigimod in reducing the severity of post-COVID-19 POTS symptoms;Evaluate the safety and tolerability of efgartigimod in patients with post-COVID-19 POTS	Evaluate the efficacy of efgartigimod in reducing the severity of post-COVID-19 POTS symptoms;Evaluate the efficacy of efgartigimod in reducing the severity of post-COVID-19 POTS symptoms;Evaluate the safety and tolerability of efgartigimod in patients with post-COVID-19 POTS